The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Wet Age Related Macular Degeneration (AMD)-Global Market Insights and Sales Trends 2024
Synopsis
Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.
The global Wet Age Related Macular Degeneration (AMD) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Wet Age Related Macular Degeneration (AMD) in various end use industries. The expanding demands from the Above 75 Years, Above 60 Years and Above 40 Years,, are propelling Wet Age Related Macular Degeneration (AMD) market. Wet Age-Related Macular Degeneration (Wet AMD), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Dry Age-Related Macular Degeneration (Dry AMD) segment is estimated at % CAGR for the next seven-year period.
Increased awareness among people about the condition has influenced the AMD treatment global demand. At the same time, the arrival of off-patent blockbuster drugs is reflecting favorably on the market particularly in third-world countries. This has allowed small-scale drug manufactures to penetrate untapped markets.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Age. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Wet Age Related Macular Degeneration (AMD), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Wet Age Related Macular Degeneration (AMD) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Wet Age Related Macular Degeneration (AMD) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Wet Age Related Macular Degeneration (AMD) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Wet Age Related Macular Degeneration (AMD) covered in this report include Novartis International (Switzerland), Bayer (Germany), Acucela (US), Neurotech Pharmaceuticals (US), Ophthotech (US), GlaxoSmithKline (US), Alimera Sciences (US), StemCell (Canada) and F. Hoffmann-La Roche (Switzerland), etc.
The global Wet Age Related Macular Degeneration (AMD) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis International (Switzerland)
Bayer (Germany)
Acucela (US)
Neurotech Pharmaceuticals (US)
Ophthotech (US)
GlaxoSmithKline (US)
Alimera Sciences (US)
StemCell (Canada)
F. Hoffmann-La Roche (Switzerland)
Regeneron Pharmaceutical (US)
Allergan (Ireland)
Adverum Biotechnologies (US)
Gilead Sciences (US)
Global Wet Age Related Macular Degeneration (AMD) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Wet Age Related Macular Degeneration (AMD) market, Segment by Type:
Wet Age-Related Macular Degeneration (Wet AMD)
Dry Age-Related Macular Degeneration (Dry AMD)
Global Wet Age Related Macular Degeneration (AMD) market, by Age
Above 75 Years
Above 60 Years
Above 40 Years
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Age, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Wet Age Related Macular Degeneration (AMD) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.
The global Wet Age Related Macular Degeneration (AMD) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Wet Age Related Macular Degeneration (AMD) in various end use industries. The expanding demands from the Above 75 Years, Above 60 Years and Above 40 Years,, are propelling Wet Age Related Macular Degeneration (AMD) market. Wet Age-Related Macular Degeneration (Wet AMD), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Dry Age-Related Macular Degeneration (Dry AMD) segment is estimated at % CAGR for the next seven-year period.
Increased awareness among people about the condition has influenced the AMD treatment global demand. At the same time, the arrival of off-patent blockbuster drugs is reflecting favorably on the market particularly in third-world countries. This has allowed small-scale drug manufactures to penetrate untapped markets.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Age. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Wet Age Related Macular Degeneration (AMD), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Wet Age Related Macular Degeneration (AMD) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Wet Age Related Macular Degeneration (AMD) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Wet Age Related Macular Degeneration (AMD) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Wet Age Related Macular Degeneration (AMD) covered in this report include Novartis International (Switzerland), Bayer (Germany), Acucela (US), Neurotech Pharmaceuticals (US), Ophthotech (US), GlaxoSmithKline (US), Alimera Sciences (US), StemCell (Canada) and F. Hoffmann-La Roche (Switzerland), etc.
The global Wet Age Related Macular Degeneration (AMD) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis International (Switzerland)
Bayer (Germany)
Acucela (US)
Neurotech Pharmaceuticals (US)
Ophthotech (US)
GlaxoSmithKline (US)
Alimera Sciences (US)
StemCell (Canada)
F. Hoffmann-La Roche (Switzerland)
Regeneron Pharmaceutical (US)
Allergan (Ireland)
Adverum Biotechnologies (US)
Gilead Sciences (US)
Global Wet Age Related Macular Degeneration (AMD) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Wet Age Related Macular Degeneration (AMD) market, Segment by Type:
Wet Age-Related Macular Degeneration (Wet AMD)
Dry Age-Related Macular Degeneration (Dry AMD)
Global Wet Age Related Macular Degeneration (AMD) market, by Age
Above 75 Years
Above 60 Years
Above 40 Years
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Age, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Wet Age Related Macular Degeneration (AMD) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Wet Age Related Macular Degeneration (AMD)
1.1 Wet Age Related Macular Degeneration (AMD) Market Overview
1.1.1 Wet Age Related Macular Degeneration (AMD) Product Scope
1.1.2 Wet Age Related Macular Degeneration (AMD) Market Status and Outlook
1.2 Global Wet Age Related Macular Degeneration (AMD) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Wet Age Related Macular Degeneration (AMD) Market Size by Region (2018-2029)
1.4 Global Wet Age Related Macular Degeneration (AMD) Historic Market Size by Region (2018-2023)
1.5 Global Wet Age Related Macular Degeneration (AMD) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Wet Age Related Macular Degeneration (AMD) Market Size (2018-2029)
1.6.1 North America Wet Age Related Macular Degeneration (AMD) Market Size (2018-2029)
1.6.2 Europe Wet Age Related Macular Degeneration (AMD) Market Size (2018-2029)
1.6.3 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size (2018-2029)
1.6.4 Latin America Wet Age Related Macular Degeneration (AMD) Market Size (2018-2029)
1.6.5 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size (2018-2029)
2 Wet Age Related Macular Degeneration (AMD) Market by Type
2.1 Introduction
2.1.1 Wet Age-Related Macular Degeneration (Wet AMD)
2.1.2 Dry Age-Related Macular Degeneration (Dry AMD)
2.2 Global Wet Age Related Macular Degeneration (AMD) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Wet Age Related Macular Degeneration (AMD) Historic Market Size by Type (2018-2023)
2.2.2 Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Wet Age Related Macular Degeneration (AMD) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Wet Age Related Macular Degeneration (AMD) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Wet Age Related Macular Degeneration (AMD) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Wet Age Related Macular Degeneration (AMD) Revenue Breakdown by Type (2018-2029)
3 Wet Age Related Macular Degeneration (AMD) Market Overview by Age
3.1 Introduction
3.1.1 Above 75 Years
3.1.2 Above 60 Years
3.1.3 Above 40 Years
3.2 Global Wet Age Related Macular Degeneration (AMD) Market Size by Age: 2018 VS 2022 VS 2029
3.2.1 Global Wet Age Related Macular Degeneration (AMD) Historic Market Size by Age (2018-2023)
3.2.2 Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Age (2024-2029)
3.3 Key Regions Market Size by Age
3.3.1 North America Wet Age Related Macular Degeneration (AMD) Revenue Breakdown by Age (2018-2029)
3.3.2 Europe Wet Age Related Macular Degeneration (AMD) Revenue Breakdown by Age (2018-2029)
3.3.3 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Revenue Breakdown by Age (2018-2029)
3.3.4 Latin America Wet Age Related Macular Degeneration (AMD) Revenue Breakdown by Age (2018-2029)
3.3.5 Middle East and Africa Wet Age Related Macular Degeneration (AMD) Revenue Breakdown by Age (2018-2029)
4 Wet Age Related Macular Degeneration (AMD) Competition Analysis by Players
4.1 Global Wet Age Related Macular Degeneration (AMD) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Wet Age Related Macular Degeneration (AMD) as of 2022)
4.3 Date of Key Players Enter into Wet Age Related Macular Degeneration (AMD) Market
4.4 Global Top Players Wet Age Related Macular Degeneration (AMD) Headquarters and Area Served
4.5 Key Players Wet Age Related Macular Degeneration (AMD) Product Solution and Service
4.6 Competitive Status
4.6.1 Wet Age Related Macular Degeneration (AMD) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis International (Switzerland)
5.1.1 Novartis International (Switzerland) Profile
5.1.2 Novartis International (Switzerland) Main Business
5.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.1.4 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis International (Switzerland) Recent Developments
5.2 Bayer (Germany)
5.2.1 Bayer (Germany) Profile
5.2.2 Bayer (Germany) Main Business
5.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.2.4 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.2.5 Bayer (Germany) Recent Developments
5.3 Acucela (US)
5.3.1 Acucela (US) Profile
5.3.2 Acucela (US) Main Business
5.3.3 Acucela (US) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.3.4 Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.3.5 Neurotech Pharmaceuticals (US) Recent Developments
5.4 Neurotech Pharmaceuticals (US)
5.4.1 Neurotech Pharmaceuticals (US) Profile
5.4.2 Neurotech Pharmaceuticals (US) Main Business
5.4.3 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.4.4 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.4.5 Neurotech Pharmaceuticals (US) Recent Developments
5.5 Ophthotech (US)
5.5.1 Ophthotech (US) Profile
5.5.2 Ophthotech (US) Main Business
5.5.3 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.5.4 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.5.5 Ophthotech (US) Recent Developments
5.6 GlaxoSmithKline (US)
5.6.1 GlaxoSmithKline (US) Profile
5.6.2 GlaxoSmithKline (US) Main Business
5.6.3 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.6.4 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.6.5 GlaxoSmithKline (US) Recent Developments
5.7 Alimera Sciences (US)
5.7.1 Alimera Sciences (US) Profile
5.7.2 Alimera Sciences (US) Main Business
5.7.3 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.7.4 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.7.5 Alimera Sciences (US) Recent Developments
5.8 StemCell (Canada)
5.8.1 StemCell (Canada) Profile
5.8.2 StemCell (Canada) Main Business
5.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.8.4 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.8.5 StemCell (Canada) Recent Developments
5.9 F. Hoffmann-La Roche (Switzerland)
5.9.1 F. Hoffmann-La Roche (Switzerland) Profile
5.9.2 F. Hoffmann-La Roche (Switzerland) Main Business
5.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.9.4 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.9.5 F. Hoffmann-La Roche (Switzerland) Recent Developments
5.10 Regeneron Pharmaceutical (US)
5.10.1 Regeneron Pharmaceutical (US) Profile
5.10.2 Regeneron Pharmaceutical (US) Main Business
5.10.3 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.10.4 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.10.5 Regeneron Pharmaceutical (US) Recent Developments
5.11 Allergan (Ireland)
5.11.1 Allergan (Ireland) Profile
5.11.2 Allergan (Ireland) Main Business
5.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.11.4 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.11.5 Allergan (Ireland) Recent Developments
5.12 Adverum Biotechnologies (US)
5.12.1 Adverum Biotechnologies (US) Profile
5.12.2 Adverum Biotechnologies (US) Main Business
5.12.3 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.12.4 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.12.5 Adverum Biotechnologies (US) Recent Developments
5.13 Gilead Sciences (US)
5.13.1 Gilead Sciences (US) Profile
5.13.2 Gilead Sciences (US) Main Business
5.13.3 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Products, Services and Solutions
5.13.4 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$ Million) & (2018-2023)
5.13.5 Gilead Sciences (US) Recent Developments
6 North America
6.1 North America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Wet Age Related Macular Degeneration (AMD) Market Dynamics
11.1 Wet Age Related Macular Degeneration (AMD) Industry Trends
11.2 Wet Age Related Macular Degeneration (AMD) Market Drivers
11.3 Wet Age Related Macular Degeneration (AMD) Market Challenges
11.4 Wet Age Related Macular Degeneration (AMD) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
